Results 331 to 340 of about 3,524,198 (392)
Some of the next articles are maybe not open access.
Resistance to Antifungal Agents
Pediatric Clinics of North America, 1995The marked increase in the number of patients with AIDS and other forms of immunocompromise has resulted in the emergence of fungi as predominant pathogens in many institutions. Unfortunately, with the widespread use of antifungal agents to combat these infections, reports of resistance to antifungal agents have proliferated. In the present environment,
Margaret K. Hostetter, Gregory P. DeMuri
openaire +3 more sources
Onychomycosis in children: Safety and efficacy of antifungal agents
Pediatric dermatology, 2018Onychomycosis is an uncommon condition in childhood, but prevalence in children is increasing worldwide.The objective was to review the efficacy and safety of systemic and topical antifungal agents to treat onychomycosis in children.
Aditya K. Gupta +4 more
semanticscholar +1 more source
Dermatologic Clinics, 2003
Currently, use of standard antifungal therapies can be limited because of toxicity, low efficacy rates, and drug resistance. New formulations are being prepared to improve absorption and efficacy of some of these standard therapies. Various new antifungals have demonstrated therapeutic potential.
Aditya K. Gupta, Elizabeth Tomas
openaire +3 more sources
Currently, use of standard antifungal therapies can be limited because of toxicity, low efficacy rates, and drug resistance. New formulations are being prepared to improve absorption and efficacy of some of these standard therapies. Various new antifungals have demonstrated therapeutic potential.
Aditya K. Gupta, Elizabeth Tomas
openaire +3 more sources
Clinical Infectious Diseases, 1992
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +3 more sources
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +3 more sources
Current Opinion in Pediatrics, 2013
In recent years there has been an evolution of a better understanding of the pharmacology and clinical indications of existing antifungal agents and also the development of new broad-spectrum triazoles and a newer class of antifungal agents, the echinocandins.
Beatriz Larru, Theoklis E. Zaoutis
openaire +3 more sources
In recent years there has been an evolution of a better understanding of the pharmacology and clinical indications of existing antifungal agents and also the development of new broad-spectrum triazoles and a newer class of antifungal agents, the echinocandins.
Beatriz Larru, Theoklis E. Zaoutis
openaire +3 more sources
Pediatric Clinics of North America, 2005
Fungal pathogens are an increasingly recognized complication of organ transplantation and the ever more potent chemotherapeutic regimens for childhood malignancies. This article provides a brief overview of the current state of systemic antifungal therapy. Currently licensed drugs, including amphotericin B and its lipid derivates; 5-fluorocytosine; the
openaire +3 more sources
Fungal pathogens are an increasingly recognized complication of organ transplantation and the ever more potent chemotherapeutic regimens for childhood malignancies. This article provides a brief overview of the current state of systemic antifungal therapy. Currently licensed drugs, including amphotericin B and its lipid derivates; 5-fluorocytosine; the
openaire +3 more sources
Antifungal agents in dermatology
Journal of the American Academy of Dermatology, 1987Development of new antifungal agents has increased significantly over the past two decades, with recent advances reflecting interest in synthetic agents as opposed to antibiotics. We review the various antifungal medications in use or under development, beginning with a discussion of over-the-counter agents, antibiotics, and older azole compounds and ...
J. Graham Smith, Jack L. Lesher
openaire +3 more sources
The Indian Journal of Pediatrics, 2001
Anti-fungal agents are classified under two major headings, systematic and topical agents. Only systematic anti-fungal agents will be discussed in this chapter. Since the discovery in 1955, amphotericin B has been the cornerstone of anti-fungal treatment. It is active against most species of fungi.
Eyassu Habte-Gabr, Walid Abuhammour
openaire +3 more sources
Anti-fungal agents are classified under two major headings, systematic and topical agents. Only systematic anti-fungal agents will be discussed in this chapter. Since the discovery in 1955, amphotericin B has been the cornerstone of anti-fungal treatment. It is active against most species of fungi.
Eyassu Habte-Gabr, Walid Abuhammour
openaire +3 more sources
Clinics in Chest Medicine, 2009
This article is a comprehensive clinically focused review of currently available antifungals administered by way of the intravenous or inhalational route: amphotericin B and its lipid formulations, fluconazole, itraconazole, posaconazole, voriconazole, caspofungin, micafungin, anidulafungin, and flucytosine.
Thomas F. Patterson +2 more
openaire +3 more sources
This article is a comprehensive clinically focused review of currently available antifungals administered by way of the intravenous or inhalational route: amphotericin B and its lipid formulations, fluconazole, itraconazole, posaconazole, voriconazole, caspofungin, micafungin, anidulafungin, and flucytosine.
Thomas F. Patterson +2 more
openaire +3 more sources
Investigational Antifungal Agents
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001Several new antifungal agents, including novel compounds in familiar classes and entirely new classes targeting previously untapped mechanisms, are in various stages of the drug development process. Many new triazole antifungal agents are being studied, including voriconazole, posaconazole, and ravuconazole.
openaire +3 more sources